BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06099184 (EYP-1901 in Diabetic Macular Edema): BVCT ex-ante prediction vs. reported outcome

On 14 Feb 2024, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 28 Oct 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient.

Clinical Trial

NCTID
NCT06099184
Acronym
VERONA
Drug Name
EYP-1901
Drug MoA
multi-kinase VEGFR/PDGFR inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Eye Diseases
Indication
Diabetic Macular Edema
Human Patients
25
Sponsor
EyePoint Pharmaceuticals
Phase
Phase 2

Prediction of , index 1463

Prospective Prediction
Prediction Index
1463
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit non-inferior to long-lasting aflibercept)
Technical Prediction
SUCCESS (statistically significant clinical benefit non-inferior to aflibercept in BCVA)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
257 days in advance
Readout Data Interpretation
EYP1901 achieved +9.9 letters in BCVA and 68 micron reduction in CST; superior to aflibercept's +3.2 letters in BCVA and 30.5 micron reduction in CST
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Diabetic Macular Edema (DME)
Phase
Phase 2
Status
Completed
Enrollment
27
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Conditions
Diabetic Macular Edema
Interventions
DRUG: EYP-1901; DRUG: Aflibercept 2Mg/0.05Ml Inj,Oph
Design
Randomized · Parallel · Single
Primary purpose
Treatment
Start
2024-01-15
Primary completion
2024-10-24
Completion
2024-10-24
Primary outcomes
  • Time to first supplemental aflibercept injection following EYP-1901 dose at Baseline vs Aflibercept (Week 24)

NCT06099184 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials